DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide.

Author(s): Duarte JD, Lobmeyer MT, Wang Z, Chapman AB, Gums JG, Langaee TY, Boerwinkle E, Turner ST, Johnson JA

Affiliation(s): Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida College of Pharmacy, Gainesville, Florida 32610, USA.

Publication date & source: 2010-08, Pharmacogenet Genomics., 20(8):516-9.

Publication type: Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

STK39 was earlier implicated as a hypertension susceptibility gene and is thought to be involved in the control of Na-Cl co-transporter activity. STK39 has been implicated as a putative thiazide diuretic response gene, as Na-Cl co-transporter activity is inhibited by thiazides. Thus, we aimed to determine whether STK39 is a thiazide response gene. One hundred and ninety-five 'good' and 194 'poor' responders to hydrochlorothiazide (HCTZ) were genotyped for approximately 100 single nucleotide polymorphisms (SNPs) within 5000 bases of STK39. SNPs meeting criteria for advancement to replication analysis (P<0.01), along with those earlier associated with hypertension, were then analyzed in a second population of 201 HCTZ-treated hypertensives. Two SNPs passed screening and were further analyzed. However, neither these, nor earlier implicated SNPs met criteria for significant association with blood pressure response to HCTZ. These data suggest that common variants in STK39 likely do not have a clinically relevant role in blood pressure response to HCTZ in hypertensives.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017